September 13, 2018
Authored and Edited by Andrew Q. Leba; Shana K. Cyr, Ph.D.
On September 4, 2018, the FDA issued final guidance on Physiologically Based Pharmacokinetic Analyses — Format and Content. The guidance outlines recommendations for the format and content of physiologically based pharmacokinetic (PBPK) analyses submitted to the FDA to support applications including INDs, NDAs, BLAs, and ANDAs. The guidance recognizes that while PBPK analyses can support decisions about clinical pharmacology studies and dosing recommendations, regulatory guidance is lacking for PBPK analysis reports, which causes significant variation in their format and content. The guidance seeks to standardize the content and format of PBPK analysis reports to assist the FDA’s regulatory review.
The FDA suggests sponsors include six sections in the report for all PBPK analyses and identifies specific information to include in each section: Executive Summary, Introduction, Materials and Methods, Results, Discussion, and Appendices. The Materials and Methods section should include sufficient information for FDA reviewers to duplicate and evaluate the modeling and simulation results, such as an overview of the modeling strategy, specification and justification of modeling parameters, a description of simulation conditions, electronic files related to modeling and software simulations, and specific software information. The Results section should demonstrate that the PBPK model is appropriate and describe the results of model application. It should present results from the methods used to verify the model, confirm model results, and conduct sensitivity analyses, and should discuss procedures used for model verification in the form of tables, graphs, and text where appropriate. The Discussion section should explain how the PBPK modeling and simulation analyses adequately address the proposed scientific, regulatory, or clinical questions, and discuss and justify any proposed dosing recommendations based on the totality of evidence. In the Appendices, the FDA recommends including a List of Tables, List of Figures, Table of Acronyms and Abbreviations, and References.
Readers are encouraged to read the final guidance, also available on the FDA’s website.
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
INCONTESTABLE® Blog
April 19, 2024
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in February 2024
April 16, 2024
INCONTESTABLE® Blog
April 12, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.